Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort

Hironobu Sunadome; Hisako Matsumoto; Yuji Tohda; Takahiko Horiguchi; Hideo Kita; Kazunobu Kuwabara; Keisuke Tomii; Kojiro Otsuka; Masaki Fujimura; Noriyuki Ohkura; Takashi Iwanaga; Soichiro Hozawa; Akio Niimi; Yoshihiro Kanemitsu; Tadao Nagasaki; Noriyuki Tashima; Yumi Ishiyama; Chie Morimoto; Tsuyoshi Oguma; Tomoko Tajiri; Isao Ito; Junya Ono; Shoichiro Ohta; Kenji Izuhara; Toyohiro Hirai

doi:10.1016/j.alit.2020.10.006

Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort

Hironobu Sunadome
, Hisako Matsumoto
, Yuji Tohda
, Takahiko Horiguchi
, Hideo Kita
, Kazunobu Kuwabara
, Keisuke Tomii
, Kojiro Otsuka
, Masaki Fujimura
, Noriyuki Ohkura
, Takashi Iwanaga
, Soichiro Hozawa
, Akio Niimi
, Yoshihiro Kanemitsu
, Tadao Nagasaki
, Noriyuki Tashima
, Yumi Ishiyama
, Chie Morimoto
, Tsuyoshi Oguma
, Tomoko Tajiri

Isao Ito, Junya Ono, Shoichiro Ohta, Kenji Izuhara, Toyohiro Hirai

Respiratory Medicine & Clinical Allergy

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	252-254
Number of pages	3
Journal	Allergology International
Volume	70
Issue number	2
DOIs	https://doi.org/10.1016/j.alit.2020.10.006
Publication status	Published - 04-2021

All Science Journal Classification (ASJC) codes

Immunology and Allergy

Access to Document

10.1016/j.alit.2020.10.006

Cite this

Sunadome, H., Matsumoto, H., Tohda, Y., Horiguchi, T., Kita, H., Kuwabara, K., Tomii, K., Otsuka, K., Fujimura, M., Ohkura, N., Iwanaga, T., Hozawa, S., Niimi, A., Kanemitsu, Y., Nagasaki, T., Tashima, N., Ishiyama, Y., Morimoto, C., Oguma, T., ... Hirai, T. (2021). Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort. Allergology International, 70(2), 252-254. https://doi.org/10.1016/j.alit.2020.10.006

@article{f96f2291b46642e1938c606d1a629494,

title = "Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort",

author = "Hironobu Sunadome and Hisako Matsumoto and Yuji Tohda and Takahiko Horiguchi and Hideo Kita and Kazunobu Kuwabara and Keisuke Tomii and Kojiro Otsuka and Masaki Fujimura and Noriyuki Ohkura and Takashi Iwanaga and Soichiro Hozawa and Akio Niimi and Yoshihiro Kanemitsu and Tadao Nagasaki and Noriyuki Tashima and Yumi Ishiyama and Chie Morimoto and Tsuyoshi Oguma and Tomoko Tajiri and Isao Ito and Junya Ono and Shoichiro Ohta and Kenji Izuhara and Toyohiro Hirai",

note = "Funding Information: HM received personal fees from AstraZeneca, Novartis Pharma, GlaxoSmithKline, and Kyorin Pharmaceutical outside the submitted work. YT reports personal fees from Kyorin Pharmaceutical, Teijin Pharma and research funding from Kyorin Pharmaceutical, Meiji Seika Pharma, Teijin Pharma, Boehringer-Ingelheim, Daiichi Sankyo, Astellas Pharma and Pearl Therapeutics outside the submitted work. KT reports a personal fee from AstraZeneca outside the submitted work. TI reports a personal fee from Kyorin Pharmaceutical and research funding from Kyorin Pharmaceutical, Meiji Seika Pharma, Boehringer-Ingelheim, Teijin Pharma, Daiichi Sankyo and Pearl Therapeutics outside the submitted work. SH reports personal fees from Astra Zeneca, GlaxoSmithKline, Novartis Pharma, Astellas Pharma, Boehringer-Ingelheim, Sanofi and Kyorin Pharmaceutical. AN reports personal fees from AstraZeneca, MSD, Nippon Boehringer-Ingelheim, Kyorin Pharmaceutical, GlaxoSmithKline, Novartis Pharma and research funding from Novartis Pharma, MSD, Nippon Boehringer-Ingelheim and Boston Scientific Japan. TO reports personal fees from AstraZeneca, Nippon Boehringer-Ingelheim, Kyorin Pharmaceutical, GlaxoSmithKline, Novartis Pharma and Sanofi and research funding from Fujifilm outside the submitted work. JO is an employee of Shino-Test. KI reports personal fees and a research funding from Shino-Test. The rest of the authors have no conflict of interest. Funding Information: HM received personal fees from AstraZeneca , Novartis Pharma , GlaxoSmithKline , and Kyorin Pharmaceutical outside the submitted work. YT reports personal fees from Kyorin Pharmaceutical , Teijin Pharma and research funding from Kyorin Pharmaceutical , Meiji Seika Pharma , Teijin Pharma , Boehringer-Ingelheim , Daiichi Sankyo , Astellas Pharma and Pearl Therapeutics outside the submitted work. KT reports a personal fee from AstraZeneca outside the submitted work. TI reports a personal fee from Kyorin Pharmaceutical and research funding from Kyorin Pharmaceutical , Meiji Seika Pharma , Boehringer-Ingelheim , Teijin Pharma , Daiichi Sankyo and Pearl Therapeutics outside the submitted work. SH reports personal fees from Astra Zeneca , GlaxoSmithKline , Novartis Pharma , Astellas Pharma , Boehringer-Ingelheim , Sanofi and Kyorin Pharmaceutical . AN reports personal fees from AstraZeneca , MSD , Nippon Boehringer-Ingelheim , Kyorin Pharmaceutical , GlaxoSmithKline , Novartis Pharma and research funding from Novartis Pharma , MSD , Nippon Boehringer-Ingelheim and Boston Scientific Japan . TO reports personal fees from AstraZeneca , Nippon Boehringer-Ingelheim , Kyorin Pharmaceutical , GlaxoSmithKline , Novartis Pharma and Sanofi and research funding from Fujifilm outside the submitted work. JO is an employee of Shino-Test. KI reports personal fees and a research funding from Shino-Test . The rest of the authors have no conflict of interest.",

year = "2021",

month = apr,

doi = "10.1016/j.alit.2020.10.006",

language = "English",

volume = "70",

pages = "252--254",

journal = "Allergology International",

issn = "1323-8930",

publisher = "Japanese Society of Allergology",

number = "2",

}

Sunadome, H, Matsumoto, H, Tohda, Y, Horiguchi, T, Kita, H, Kuwabara, K, Tomii, K, Otsuka, K, Fujimura, M, Ohkura, N, Iwanaga, T, Hozawa, S, Niimi, A, Kanemitsu, Y, Nagasaki, T, Tashima, N, Ishiyama, Y, Morimoto, C, Oguma, T, Tajiri, T, Ito, I, Ono, J, Ohta, S, Izuhara, K & Hirai, T 2021, 'Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort', Allergology International, vol. 70, no. 2, pp. 252-254. https://doi.org/10.1016/j.alit.2020.10.006

Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort. / Sunadome, Hironobu; Matsumoto, Hisako; Tohda, Yuji et al.
In: Allergology International, Vol. 70, No. 2, 04.2021, p. 252-254.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future

T2 - A follow-up study of the KiHAC cohort

AU - Sunadome, Hironobu

AU - Matsumoto, Hisako

AU - Tohda, Yuji

AU - Horiguchi, Takahiko

AU - Kita, Hideo

AU - Kuwabara, Kazunobu

AU - Tomii, Keisuke

AU - Otsuka, Kojiro

AU - Fujimura, Masaki

AU - Ohkura, Noriyuki

AU - Iwanaga, Takashi

AU - Hozawa, Soichiro

AU - Niimi, Akio

AU - Kanemitsu, Yoshihiro

AU - Nagasaki, Tadao

AU - Tashima, Noriyuki

AU - Ishiyama, Yumi

AU - Morimoto, Chie

AU - Oguma, Tsuyoshi

AU - Tajiri, Tomoko

AU - Ito, Isao

AU - Ono, Junya

AU - Ohta, Shoichiro

AU - Izuhara, Kenji

AU - Hirai, Toyohiro

N1 - Funding Information: HM received personal fees from AstraZeneca, Novartis Pharma, GlaxoSmithKline, and Kyorin Pharmaceutical outside the submitted work. YT reports personal fees from Kyorin Pharmaceutical, Teijin Pharma and research funding from Kyorin Pharmaceutical, Meiji Seika Pharma, Teijin Pharma, Boehringer-Ingelheim, Daiichi Sankyo, Astellas Pharma and Pearl Therapeutics outside the submitted work. KT reports a personal fee from AstraZeneca outside the submitted work. TI reports a personal fee from Kyorin Pharmaceutical and research funding from Kyorin Pharmaceutical, Meiji Seika Pharma, Boehringer-Ingelheim, Teijin Pharma, Daiichi Sankyo and Pearl Therapeutics outside the submitted work. SH reports personal fees from Astra Zeneca, GlaxoSmithKline, Novartis Pharma, Astellas Pharma, Boehringer-Ingelheim, Sanofi and Kyorin Pharmaceutical. AN reports personal fees from AstraZeneca, MSD, Nippon Boehringer-Ingelheim, Kyorin Pharmaceutical, GlaxoSmithKline, Novartis Pharma and research funding from Novartis Pharma, MSD, Nippon Boehringer-Ingelheim and Boston Scientific Japan. TO reports personal fees from AstraZeneca, Nippon Boehringer-Ingelheim, Kyorin Pharmaceutical, GlaxoSmithKline, Novartis Pharma and Sanofi and research funding from Fujifilm outside the submitted work. JO is an employee of Shino-Test. KI reports personal fees and a research funding from Shino-Test. The rest of the authors have no conflict of interest. Funding Information: HM received personal fees from AstraZeneca , Novartis Pharma , GlaxoSmithKline , and Kyorin Pharmaceutical outside the submitted work. YT reports personal fees from Kyorin Pharmaceutical , Teijin Pharma and research funding from Kyorin Pharmaceutical , Meiji Seika Pharma , Teijin Pharma , Boehringer-Ingelheim , Daiichi Sankyo , Astellas Pharma and Pearl Therapeutics outside the submitted work. KT reports a personal fee from AstraZeneca outside the submitted work. TI reports a personal fee from Kyorin Pharmaceutical and research funding from Kyorin Pharmaceutical , Meiji Seika Pharma , Boehringer-Ingelheim , Teijin Pharma , Daiichi Sankyo and Pearl Therapeutics outside the submitted work. SH reports personal fees from Astra Zeneca , GlaxoSmithKline , Novartis Pharma , Astellas Pharma , Boehringer-Ingelheim , Sanofi and Kyorin Pharmaceutical . AN reports personal fees from AstraZeneca , MSD , Nippon Boehringer-Ingelheim , Kyorin Pharmaceutical , GlaxoSmithKline , Novartis Pharma and research funding from Novartis Pharma , MSD , Nippon Boehringer-Ingelheim and Boston Scientific Japan . TO reports personal fees from AstraZeneca , Nippon Boehringer-Ingelheim , Kyorin Pharmaceutical , GlaxoSmithKline , Novartis Pharma and Sanofi and research funding from Fujifilm outside the submitted work. JO is an employee of Shino-Test. KI reports personal fees and a research funding from Shino-Test . The rest of the authors have no conflict of interest.

PY - 2021/4

Y1 - 2021/4

UR - https://www.scopus.com/pages/publications/85097216243

UR - https://www.scopus.com/pages/publications/85097216243#tab=citedBy

U2 - 10.1016/j.alit.2020.10.006

DO - 10.1016/j.alit.2020.10.006

M3 - Letter

C2 - 33218953

AN - SCOPUS:85097216243

SN - 1323-8930

VL - 70

SP - 252

EP - 254

JO - Allergology International

JF - Allergology International

IS - 2

ER -

Assessment of serum periostin level as a predictor of requirement for intensive treatment for type-2 inflammation in asthmatics in future: A follow-up study of the KiHAC cohort

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this